All In Biotech

Drug Trial Radar · NCT00129181

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Aug 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 2005

Primary completion

Dec 2006

Study completion Jan 2007

Sponsor

Lead sponsor
Institute for Neurodegenerative DisordersAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer; GE Healthcare
First posted
Aug 11, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane (\[123I\]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.

Conditions

  • Parkinson Disease
  • Parkinsonian Syndrome

Interventions

  • cabergolineDrug

    Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).

  • carbidopa/levodopaDrug

    Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).

  • DATscan and SPECT imagingProcedure

    Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the influence of short-term levodopa therapy on dopamine transporter density in early Parkinson's diseaseTime frame: 1 year

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Department of Neurology, Innsbruck Medical University

    Innsbruck, Austria

  • Neurological Department, Wilhelminenspital

    Vienna, Austria

  • Dept. of Neurology, University of Leipzig

    Leipzig, Germany

  • Dept. of Neurology Marburg, Phillips-Univ.

    Marburg, Germany

  • Ambulanz für Bewegungsstörungen, Neurologische Poliklinik

    München, Germany

  • University of Catania-Department of Neurosciences

    Catania, Italy

  • Parkinson Institute Milan

    Milan, Italy

  • Department of Neurological Sciences-University of Napoli

    Naples, Italy

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.